Viewing Study NCT04780568


Ignite Creation Date: 2025-12-24 @ 5:36 PM
Ignite Modification Date: 2025-12-27 @ 12:28 PM
Study NCT ID: NCT04780568
Status: RECRUITING
Last Update Posted: 2025-12-09
First Post: 2021-02-28
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer
Sponsor: Ohio State University Comprehensive Cancer Center
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module